Seeking Alpha

Bret Jensen

 
View as an RSS Feed
View Bret Jensen's Articles BY TICKER:
A, AA, AAPL, AAWW, ABB, ABT, ABTL, ABX, ACET, ACLS, ACMP, ACTG, ACTV, ADBE, ADSK, AEP, AER, AGCO, AGEN, AGU, AHH, AHT, AIG, AKS, ALJ, ALL, ALR, AMAT, AMGN, AMKR, AMTD, AMZG, AMZN, ANF, ANIK, ANV, APA, APC, APEI, APL, ARCP, ARII, ARLP, ARO, ARP, ASH, ATRS, ATSG, ATU, ATVI, ATW, AU, AVGO, AVNR, AXAS, AXTI, AYR, AZN, BA, BAC, BAS, BAX, BBBY, BBEP, BBRY, BBT, BBW, BBY, BCEI, BGC, BGFV, BHI, BIDU, BIG, BIIB, BIOL, BK, BKCC, BKH, BKW, BLK, BMO, BMR, BNS, BP, BRCD, BRCM, BRKS, BTU, BWP, BX, BYI, C, CALL, CARB, CAT, CBI, CBOU, CDE, CELG, CEO, CERS, CGIX, CGR, CHK, CHKP, CHL, CHMT, CJES, CKSW, CLDT, CLF, CLMT, CLR, CMG, CMI, CMLP, CNAT, CNDO, CNP, CNQ, CNQR, CNX, COF, COG, COH, COOL, COP, CORT, COV, CPE, CPIX, CPNO, CPSI, CRM, CROX, CRUS, CRZO, CSCO, CSX, CTCM, CVE, CVS, CVX, CXPO, CXS, CY, DAKT, DAN, DD, DDE, DE, DECK, DELL, DENN, DG, DIS, DK, DNR, DO, DOW, DPM, DRH, DRIV, DSCO, DTLK, DTV, DUSA, DVAX, DVN, DVR, DWA, DXLG, DY, E, EBAY, ECA, ECPG, EDR, ELY, EMC, END, ENDP, EOG, EOX, EPAM, EPAX, EPB, EPD, EPIQ, EPR, EQM, EROC, ESIO, ESV, ETE, ETN, ETP, ETRM, EVEP, EWZ, EXK, EXLP, EXXI, F, FANG, FB, FCH, FCX, FDX, FIG, FLL, FLR, FLY, FOLD, FOSL, FRD, FSC, FSII, FST, FURX, FWLT, FXCM, GA, GBX, GCOM, GD, GE, GEF, GEL, GEOY, GERN, GES, GEVA, GFI, GILD, GLP, GLUU, GLW, GM, GNMK, GNW, GOLD, GOOG, GOOGL, GPOR, GPS, GS, GSK, GSM, GSS, GTATQ, GTE, HAL, HAR, HBM, HCLP, HEP, HERO, HES, HFC, HIG, HK, HL, HLF, HLX, HMA, HON, HOS, HP, HPQ, HPT, HRS, HRZN, HTA, HTGC, HTLF, HURN, HZNP, IACI, IAG, IGTE, INN, INT, INTC, INVN, IO, IP, IPGP, IQNT, IRDM, IRET, IRT, ISRG, ISSI, ITRI, ITT, IVAC, IVAN, JAZZ, JDSU, JEC, JNJ, JNPR, JOY, JPM, KBH, KBR, KCAP, KDN, KEG, KERX, KEYN, KFY, KKR, KLAC, KLIC, KO, KOG, KONA, KR, KRA, KRG, KRO, LAD, LCI, LGCY, LIFE, LIME, LINE, LLL, LLNW, LLY, LMOS, LMT, LNCO, LNKD, LO, LOCO, LOW, LPRI, LPX, LRE, LSI, LUK, LULU, LVS, LXP, LYB, M, MAN, MANT, MCEP, MCGC, MCHX, MCP, MDR, MDT, MEI, MELI, MEMP, MET, MHR, MIND, MITL, MMLP, MMP, MNK, MO, MOD, MOS, MPC, MPO, MPW, MRCY, MRGE, MRK, MRO, MRVL, MS, MSFT, MT, MTDR, MTOR, MTSN, MU, MUR, MXIM, MYL, MYRG, NAVB, NBL, NBR, NCT, NE, NEE, NEM, NEON, NFLX, NFX, NGLS, NGPC, NIHD, NILE, NOG, NOK, NOV, NPTN, NR, NSC, NSPH, NTAP, NTSP, NUAN, NVAX, NVDA, NVS, NWY, NXPI, NYCB, NYX, OAK, OAS, OCN, OCZ, OHI, OI, OIS, OKS, OME, OPLK, ORAN, ORBK, ORCL, ORIG, ORLY, OUTR, OVTI, OXY, OZM, PAA, PAAS, PACD, PACR, PANW, PAYX, PBF, PBH, PBI, PBY, PCLN, PCTI, PDH, PDLI, PDS, PEET, PEG, PES, PETM, PETS, PFE, PFMT, PGEM, PH, PKT, PKY, PLAB, PM, PNC, PNG, PNK, PNRA, POM, POT, PRTA, PRU, PSX, PTEN, PTX, PULB, PVR, PWER, QCCO, QCOM, QLGC, QLTY, QRE, QUMU, R, RAIL, RAX, RCL, RDC, RDWR, REGN, RES, REXX, RF, RFMD, RHI, RHT, RIG, RIGL, RIO, RNET, RNN, ROC, ROSE, ROVI, RPRX, RPTP, RRD, RSTI, RTEC, RTN, RUE, RUTH, RVBD, SAM, SARA, SBRA, SCLN, SCMR, SD, SDRL, SEAC, SFY, SGY, SHOR, SIGA, SIMG, SIMO, SIRI, SKUL, SLB, SLCA, SLTM, SLW, SM, SMCI, SN, SNH, SNY, SODA, SPLK, SPLS, SPN, SPPI, SPRT, SPY, SQNM, SSH, SSNLF, STI, STJ, STKL, STMP, STO, STT, STX, SUNE, SVU, SWFT, SWKS, SYMC, SYNA, SYPR, SYRG, SYY, T, TAL, TAP, TBT, TC, TCAP, TDW, TEF, TER, TESO, TEVA, TEX, TGX, TICC, TIVO, TKR, TLLP, TLM, TMO, TOT, TPC, TPLM, TQNT, TRLG, TRN, TRP, TSLA, TSO, TST, TSYS, TTI, TWC, TWI, TWO, TWX, UA, UNH, UNIS, UNT, UPL, URI, USB, V, VALE, VELTF, VICL, VLO, VMW, VNR, VOD, VRA, VSEC, VXX, VZ, WAC, WAG, WDC, WEN, WFC, WFT, WHR, WIFI, WLL, WMT, WRES, XEC, XOM, XRX, YELP, YHOO, Z, ZAGG, ZEUS, ZIXI, ZLTQ, ZNGA
  • Navidea Pharmaceuticals: An Update On My $2 Biotech Lottery Ticket
    Tue, Dec. 23 NAVB 24 Comments

    Summary

    • It seems time for an investment update on small biotech Navidea Pharmaceuticals given the stock's recent rally and positive developments at the company.
    • Navidea is expanding the geographical footprint of its main product Lymposeek and has made the decision to pursue therapeutic opportunities.
    • These are positive developments that could drive still substantial upside at this small speculative opportunity for aggressive growth investors in the biotech space.
  • My Predictions For 2015 - Part I
    Tue, Dec. 23 SPY, VGK, OIL 105 Comments

    Summary

    • With only a few more trading sessions left in 2014, it is the time of the year financial commentators offer up their predictions for the New Year.
    • This is the first of a three part series that will look at two macro trends that should continue, what's ahead for the market and some good stocks to own.
    • Today we look at why oil should end higher than its current levels and why the Eurozone will continue to show disappointing growth facilitating a further slide in the euro.
  • Oasis Petroleum: High Risk/High Reward Oil Play
    Mon, Dec. 22 OAS 19 Comments

    Summary

    • After three months of a deep consistent decline, the exploration & production sector finally had a significant surge in the market this week as oil prices started to stabilize.
    • Sometimes the best time to invest is when there is "blood in the streets". The E&P sector certainly qualifies. Encouragingly insiders are also increasing their purchases in this space recently.
    • One stock with recent insider activity is Bakken play Oasis Petroleum. Why I believe this energy concern will be a long term winner for patient investors is detailed below.
  • Gilead: What's Ahead In 2015 For This Biotech Juggernaut
    Sat, Dec. 20 GILD 413 Comments

    Summary

    • Biotech juggernaut Gilead Sciences has provided its shareholders with better than a 30% gain in 2014 so far as we head into the end of the year.
    • Although the stock has spent the last three months consolidating those gains in a relatively narrow trading range, the direction for 2015 remains up.
    • Gilead has several major positive catalysts on the horizon in 2015. Why I believe the stock will head much higher in the twelve months ahead is detailed below.
  • Micron: A Big Value Story Most Of The Market Is Missing
    Thu, Dec. 18 MU 51 Comments

    Summary

    • After a very solid first half of 2014, the stock of Micron has spent the last six months moving in a relatively narrow trading range consolidating first half gains.
    • However, core business fundamentals are improving, the stock is very cheap and earnings estimates continue to rise.
    • Why I believe the stock has 40% to 50% upside over the next 12 months is profiled below.
  • Procera Networks: A Cash Rich Small-Cap Gem To Consider
    Wed, Dec. 17 PKT 5 Comments

    Summary

    • Beaten down Procera Networks is rallying today on the announcement of some new orders and this could be the start of a significant rally in the stock.
    • The shares have had a tough year as the stock has been cut in half from earlier highs as revenue growth failed to materialize during the year.
    • However, the company has a cash rich balance sheet, activist funds are circling and positive catalysts are on the horizon. The environment is starting to look brighter for Procera.
  • Time To Buy Boeing
    Wed, Dec. 17 BA 27 Comments

    Summary

    • The market just had its worse week in more than two years and that pullback has extended into this week.
    • The decline in equities has started to yield some solid entry points on some strong businesses, one of these is Boeing which has a massive order backlog.
    • The company also just announced it is rewarding shareholders by increasing its dividend and stock repurchase program. Why the stock is a good value here is detailed below.
  • Plays For The Euro Heading To Parity To The Dollar
    Mon, Dec. 15 FXE, UUP, MCD 51 Comments

    Summary

    • Barron's had a good piece in this weekend's magazine speculating the recent fall in the euro will take the currency to parity to the dollar in 1-2 years.
    • This seems a likely occurrence given the divergence of the two continents' economic performance and the need of the European Central Bank to engage in further quantitative easing.
    • What this likely convergence will mean for the markets, and some ideas on how to play this upcoming parity.
  • The Collapse In Oil Prices Rocks The Markets
    Sat, Dec. 13 OIL, CRUD, USO 71 Comments

    Summary

    • The oil markets continued their free fall last week. The accelerating decline in oil prices was a key factor to the big plunge in the markets this week.
    • The speed of the fall in crude is causing some severe dislocations in the economy and the market that investors should be aware of.
    • The market could remain very volatile until oil prices stabilize. The three main negative impacts of falling oil prices are profiled below.
  • Conatus Pharmaceuticals: A Potential Double Worth Consideration
    Sat, Dec. 13 CNAT 6 Comments

    Summary

    • The biotech sector continues to hold up well despite the recent carnage in specific other sectors of the market triggered by the deep declines in the oil market.
    • I continue to find worthy if speculative plays within the small biotech sector. Investors should diversify to a greater degree within the sector due to the volatility in the space.
    • One small cap that has behaved well since I profiled it in August is Conatus Pharmaceuticals. Why I am optimistic about additional potentially significant upside in 2015 is profiled below.
  • Chatham Lodging Trust: Still An Attractive Yield Play
    Fri, Dec. 12 CLDT 8 Comments

    Summary

    • The high yield space has been challenging of late with poor performance from both upstream energy partnerships and business development companies.
    • I continue to prefer real estate investment trusts for income as valuations are reasonable and interest rates should remain historically low for the foreseeable future.
    • My favorite area within the REIT space is lodging due to its improving business fundamentals. That's why Chatham Lodging Trust remains a core position within that industry in my portfolio.
  • Avago Technologies: A Blue-Chip Gem For The Holidays
    Thu, Dec. 11 AVGO 9 Comments

    Summary

    • Avago Technologies has more than tripled since I identified it as a great play on the huge LTE rollout happening in this country.
    • The company continues to hit on all cylinders and recently delivered a stellar quarterly earnings report.
    • Despite the huge run up in the shares of this blue-chip gem, the stock still sports an attractive valuation given its continued growth prospects.
  • Dow 18,000? Not So Fast
    Thu, Dec. 11 DIA, SPY, QQQ 30 Comments

    Summary

    • After advancing for six weeks in a row, the market is selling off this week on a variety of factors such as the implosion of oil prices.
    • Equities were overdue for a rally and it is becoming obvious that there are some major concerns investors should be aware of.
    • It feels like we could be in the middle of a decent pullback and caution continues to be call for at this point in time.
  • DynaVax Technologies: The Small Cap Gem Focus Stock Of The Week
    Wed, Dec. 10 DVAX 9 Comments

    Summary

    • The small cap biotech area has been a strong performer of late mitigating some of the pain in the small cap energy sector.
    • There are several things I look for when making an investment in this space including a promising pipeline, cash on hand and partnerships with major players in pharma or biotech.
    • DynaVax Technologies fits that bill and is why I have a small position in this high risk/high reward play.
  • The Contagion From The Imploding Oil Market Spreads
    Tue, Dec. 9 CHK, OIL, SLCA 108 Comments

    Summary

    • The fall in oil prices has decimated the stocks of exploration & production concerns as well as energy services companies.
    • This contagion is starting to spread to other sectors of the market and the economy and has been a factor in the decline of the overall market this week.
    • This development bears watching and could be one of the primary factors in determining market direction over the next few months.
  • Tutor Perini: An Oversold Small-Cap Gem
    Mon, Dec. 8 TPC 54 Comments

    Summary

    • This week's small-cap stock focus article revolves around Tutor Perini, a construction firm whose stock has sold off 20% over the past three months.
    • This presents a great long-term entry point on a company with a large and growing order backlog and which is benefiting from a decision to diversify its income streams.
    • No wonder how one slices the company, the stock is cheap and earnings are set to grow 20% annually.
  • Google: A Blue Chip Gem For 2015
    Mon, Dec. 8 GOOGL, GOOG 47 Comments

    Summary

    • Google has not participated in the bullish rally many tech stocks have been on in 2014.
    • The company still has plenty of growth drivers and hidden assets.
    • Investors should consider Google in large-cap growth portfolios.
  • 2 Core Holdings That Belong In Every Biotech Portfolio
    Mon, Dec. 8 CELG, GILD 27 Comments

    Summary

    • I love writing and investing in the small cap biotech space as few areas can bring investors such outsized returns when things go right.
    • However, given the volatility of the space, lack of earnings visibility and high failure rates; most of my biotech portfolio consists of large cap growth plays with reasonable valuations.
    • Profiled below are my two biggest biotech holdings. Both are solid values given their growth prospects and should provide investors with superior returns again in 2015.
  • Why Gilead Is A Better Buy Than AbbVie
    Fri, Dec. 5 GILD 96 Comments

    Summary

    • The stock price appreciation of biotech juggernaut Gilead Sciences has stalled recently as the biotech giant consolidates recent gains and as some worries about competition in hepatitis C space increases.
    • I have seen a lot of comments and commentary around how AbbVie could be a major player in the hepatitis C arena in the medium term.
    • My opinion is that those worries are unwarranted, the stock is ridiculously cheap and certainly a better long term buy than that of AbbVie.
  • Biogen: Big Biotech Play Ready To Move
    Wed, Dec. 3 BIIB 15 Comments

    Summary

    • The stock of Biogen Idec is on the move today on encouraging results from early stage trials for its investigative drug for the treatment of Alzheimer's patients.
    • Given the size of the potential market, this drug could be a potential blockbuster. However, Biogen also has a very deep pipeline of drugs in early and late stage development.
    • The company also has three drugs that generate over $500 million a quarter in revenue and the stock is cheap given its growth trajectory.
  • ConocoPhillips: High Yield Play Will Survive Crash In Oil Prices
    Tue, Dec. 2 COP 54 Comments

    Summary

    • The recent $40 a barrel plunge in oil has caused chaos across the stocks in the energy sector. Particularly decimated has been the E&P space.
    • It is impossible to predict when and where the fall in oil prices will end, but it will end as most OPEC countries cannot sustain this over the long term.
    • It is time to slowly and incrementally start to bottom fish in the sector in anticipation of some normalcy returning to energy pricing.
    • ConocoPhillips is the perfect high yield play to begin that process. It will survive this huge sell-off and might even benefit on certain aspects of this plunge.
  • 3 Worries For December
    Tue, Dec. 2 DIA, SPY, QQQ 43 Comments

    Summary

    • After rallying over the last six weeks, the market began the month of December on a down note as the recent plunge in oil prices continues to cause some pain.
    • This sudden and sharp decline in oil and its impact on both the equity and credit markets lead my reasons for concern about market performance in December.
    • Investors seem to have forgotten the steep market sell-off of mid-September. Why I doubt we will get a Santa Claus rally this year and my outlook for December outlined below.
  • General Motors: Buy Now While Priced At Discount
    Mon, Dec. 1 GM 44 Comments

    Summary

    • General Motors has had a rough year as the company has been pummeled by a huge recall crisis and losses in its European Operations.
    • The shares have underperformed the overall S&P 500 by about 25% this year as a result.
    • However, brighter days look ahead in the coming year. Investors should scoop up these cheap shares prior to the New Year as they are likely to outperform market in 2015.
  • Micron Could Hit $50 In 2015
    Sat, Nov. 29 MU 70 Comments

    Summary

    • The stock of Micron, after a brief pause, has resumed its rise, contributing to an already stellar performance so far in 2014.
    • Investors have been slow to price in the beneficial changes in the company's core DRAM market which should lead to further gains in 2015.
    • Despite the stock's rise in 2014, the shares are still cheap. Earnings estimates keep rising and the stock could easily hit $50 a share over the next 12-18 months.
  • Hewlett-Packard: Still Momentum In Its Turnaround Story
    Sat, Nov. 29 HPQ 10 Comments

    Summary

    • Hewlett-Packard shareholders continue to be rewarded as the company executes against its turnaround plan, an effort that has seen the stock double over the past two years.
    • The company just delivered another solid quarterly report where it reported that margins are seeing improvement across its line of businesses.
    • Even with the impressive rally over the past 24 months, the stock is still selling at a deep discount to the overall market. Positive catalysts remain ahead in 2015.
  • The Gap: A Good Turnaround Story For 2015
    Wed, Nov. 26 GPS 11 Comments

    Summary

    • I have always been fascinated by turnaround stories in the market. I have found these equities have provided some of the best returns in my portfolio over the years.
    • The Gap fits that mold right now as it has brought in new management, upped its buyback plan and is making other operational improvements.
    • The shares are relatively cheap and should benefit from falling gas prices and a stronger dollar. The retailer should provide solid returns to investors in 2015.
  • Micron: The Breakout Arrives
    Tue, Nov. 25 MU 33 Comments

    Summary

    • My regular readers know that I have been a big bull on Micron since the stock slumped recently in a overreaction to possible new capacity additions to its sector.
    • That patience is starting to be rewarded as the shares look like they are breaking out to the upside from a recent trading range.
    • Why I believe this cheap tech stock has substantial gains ahead in the months ahead is profiled below.
  • Despite Recent Hiccup, Gilead Is Still A Blue Chip Gem
    Tue, Nov. 25 GILD 148 Comments

    Summary

    • Biotech juggernaut Gilead Sciences is giving investors a great buying opportunity for the second time in 2014 after a recent 15% pullback in the stock price.
    • Even as the stock has declined recently, earnings estimates have increased for 2015 and the company has plenty of positive catalysts ahead.
    • Gilead is one of the cheapest large cap growth plays in the market and I believe over the next 12 months the shares could rise 50% from current levels.
  • Some Small Cap Gems In Housing To Consider
    Mon, Nov. 24 TPH, BZH 4 Comments

    Summary

    • As trading in 2014 is fast coming to a close it is time to start thinking about what sectors could outperform in 2015 delivering upside for investors.
    • With the housing market starting to post some better numbers, this sector laggard appears to have a chance to be a key story in 2015.
    • Some attractive small cap plays that will benefit if the housing market does accelerate in 2015 are profiled below.
  • 2 Possible Small Cap Gems To Consider As 2015 Approaches
    Sat, Nov. 22 AXAS, EXK 24 Comments

    Summary

    • The end of 2014 is fast approaching and the year has been a much more uneven one for traders than the previous year.
    • It is time to look through some of the carnage of sectors that were sold off substantially during the year for possible winners in the New Year.
    • Profiled below are two possible small cap gems selling for less than $5 a share that could soar in 2015 if sentiment just improves just a little in their sectors.
  • How To Play The Polar Vortex Version 2.0
    Tue, Nov. 18 TPC, GNRC, WRES 171 Comments

    Summary

    • Predictions of a mild winter seem to be eroding as it appears Polar Vortex version 2.0 is descending across the nation with most of the country in deep freeze.
    • It is important to remember that last year's horrid winter caused the economy to contract in the first quarter and also produced winners in some cold winter plays.
    • Profiled below are a couple of small cap stocks that could significantly benefit if the country does experience a repeat of last winter.
  • Both I And Barron's Believe Ford Has 30% Upside In 2015
    Tue, Nov. 18 F 45 Comments

    Summary

    • Barron's makes the case for American manufacturer icon Ford in the New Year postulating they should have 30% upside from current levels in 2015.
    • The piece makes some of the same salient points I have made on the investment case for Ford recently as well as a few new ones.
    • Investors looking for a good growth story with a high dividend yield selling at very reasonable valuations should take Ford for a ride in the New Year.